Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 2

of 'Treatment of relapsed or refractory multiple myeloma'

Clinically relevant end points and new drug approvals for myeloma.
Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P, ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma
Leukemia. 2008;22(2):231. Epub 2007 Nov 1.
This manuscript summarizes the recommendations of the American Society of Hematology/US Food and Drug Administration Workshop on Clinical Endpoints in Multiple Myeloma, which brought together clinical investigators in multiple myeloma, the United States Food and Drug Administration, pharmaceutical companies, patient advocates and other concerned scientists and physicians to provide guidance, consensus and consistency in the definition of clinically relevant end points to expedite new drug approvals for multiple myeloma in the appropriate trial design settings. This manuscript will therefore be a most valuable resource to provide the framework for the design of appropriate clinical trial strategies for more rapid new drug approval in myeloma.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. kenneth_anderson@dfci.harvard.edu